SS-31 (Elamipretide)
elamipretide · MTP-131 · Bendavia · C32H49N9O5 · monoisotopic 639.3856 Da. The index holds 124 assay reports on this compound across 24 batches from 15 suppliers.
Analytical fingerprint
Hand-authored chemistry. These properties describe the substance and do not change when a record is added.
A tetrapeptide, so the assay is straightforward and the achievable purity is high — SS-31's index median is the highest of any compound tracked here (99.2 %, n over 200). At that level the interesting question stops being purity and becomes counter-ion and water: elamipretide as an acetate salt commonly carries 6–9 % water, which means a nominal 50 mg vial contains materially less than 50 mg of peptide. The purity→mass correction calculator exists mostly for compounds like this one.
- Compound class
- Metabolic and mitochondrial peptides
- Molecular formula
- C32H49N9O5
- Monoisotopic mass
- 639.3856Da
- Average mass
- 639.79Da
- Residues
- 4
- Nominal retention (RG-2, 30 min)
- 8.94min
- Retention window
- 0.25min
- Counter-ion as usually shipped
- acetate
- Typical label claims
- 10 mg · 20 mg · 50 mg
- Analytical difficulty (index scale)
- 0.85 — straightforward
- Purity is a defined quantity
- YES
Representative chromatogram
Drawn from this page's own medians. Not a scan, not an illustration, and not any single report.
What the index has observed
Arithmetic over the 124 records the index holds. Aggregates on this page are computed over the records the index holds, which are not a random sample of the material on the market. Lots that get tested are lots someone chose to test. Read every figure here as a description of this dataset rather than as an estimate of a population.
By supplier
Suppliers with fewer than two purity records on this compound are omitted from the figure rather than drawn as a line. The full table, including the thin cells, is on the by-supplier page.
Characteristic impurities and degradants
The left three columns are authored chemistry — what this molecule characteristically carries and where it elutes. The right three are what the index has actually reported.
| Named species | ΔRT (min, RG-2) | Δ mass (Da) | Seen in | Median % area | Max % area |
|---|---|---|---|---|---|
| [D-Arg1]-epimer | -0.18 | mass-identical | 93% | 0.11 | 1.27 |
| acetyl adduct (+42 Da) | +0.54 | +42.011 | 89% | 0.10 | 1.59 |
| des-Dmt (−193 Da) | -0.72 | -193.110 | 87% | 0.10 | 0.58 |
| C-terminal free acid (+1 Da) | +0.20 | +0.984 | 85% | 0.12 | 1.07 |
Degradation pathways
- C-terminal amide hydrolysis
- epimerisation at Arg1 under prolonged basic coupling
Full impurity profile, with what each named species implies about the synthesis →
Clinical context
Included because it is routinely misapplied. Trial data describes a licensed medicinal product manufactured under a marketing authorisation, and it does not transfer to research-grade material of unknown provenance.
Elamipretide has been studied in primary mitochondrial myopathy and Barth syndrome; results have been mixed and no product is approved.